We think that R&D has been woefully under-served by advisory firms for years. We also think R&D is the engine of value creation in Biopharma and that it’s about time it was treated as such.

Hint: The number of days you can shave off a timeline does not automatically translate into downstream revenue.

Patient Safety, Regulatory Compliance and Well-Formulated Studies are the job and are already priced in….

Or widget manufacturing, or airlines, or Uber, or whatever. Don’t get me wrong, I love a metaphor. A good metaphor is worth a thousand pictures. But drug development is a truly unique enterprise that has defied many hype cycles before.